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Abstract
Background—Vietnam has high endemic hepatitis B virus infection with >8% of adults 
estimated to have chronic infection. Hepatitis B vaccine was first introduced in the national 
childhood immunization program in 1997 in high-risk areas, expanded nationwide in 2002, and 
included birth dose vaccination in 2003. This survey aimed to assess the impact of Vietnam’s 
vaccination programme by estimating the prevalence of hepatitis B surface antigen (HBsAg) 
among children born during 2000–2008.
Methods—This nationally representative cross-sectional survey sampled children based on a 
stratified three-stage cluster design. Demographic and vaccination data were collected along with 
a whole blood specimen that was collected and interpreted in the field with a point-of-care HBsAg 
test.
Results—A total of 6,949 children were included in the survey analyses. The overall HBsAg 
prevalence among surveyed children was 2.70% (95% confidence interval (CI): 2.20–3.30). 
However, HBsAg prevalence was significantly higher among children born in 2000–2003 (3.64%) 
compared to children born 2007–2008 (1.64%) (prevalence ratio (PR: 2.22, CI 1.55–3.18)). 
Among all children included in the survey, unadjusted HBsAg prevalence among children with ≥3 
doses of hepatitis B vaccine including a birth dose (1.75%) was significantly lower than among 
children with ≥3 doses of hepatitis B vaccine but lacked a birth dose (2.98%) (PR: 1.71, CI: 1.00–
2.91) and significantly lower than among unvaccinated children %) (PR: 1.99, CI: 1.15–3.45). 
Infants receiving hepatitis B vaccine >7 days after birth had significantly higher HBsAg 
prevalence (3.20%) than those vaccinated 0-1 day after birth (1.52%) (PR: 2.09, CI: 1.27–3.46).
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Conclusion—Childhood chronic HBV infection prevalence has been markedly reduced in 
Vietnam due to vaccination. Further strengthening of timely birth dose vaccination will be 
important for reducing chronic HBV infection prevalence of under 5 children to <1%, a national 
and Western Pacific regional hepatitis B control goal.
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1. Introduction
Hepatitis B virus (HBV) infection is highly endemic in Vietnam with an estimated chronic 
infection prevalence among adults of 8–20% [1–4]. A survey in two districts in Thanh Hoa 
Province in 1998 showed prevalence of HBsAg, a marker for chronic HBV infection, to be 
12% among infants, 18% among children (4–5 years), 20% among adolescents (14–15 
years), and 19% among adults (25–39 years) [5]. HBV is a known carcinogen and the high 
prevalence of chronic HBV infection is an important contributing factor to liver cancer and 
cirrhosis, which is the most common cause of cancer death in Vietnam [6–8].
Like other countries in South East and Eastern Asia, the primary routes of HBV 
transmission in Vietnam are from mother-to-child or from close contacts during early 
childhood [9]. Hepatitis B vaccine is highly effective in preventing both perinatally and 
horizontally acquired chronic HBV infection [10–12]. Therefore, to reduce chronic HBV 
infection prevalence and protect children from infection, Vietnam introduced hepatitis B 
vaccine in the national immunization program in 1997 in selected areas. Infant hepatitis B 
vaccination program was expanded nationwide in 2002 and a monovalent hepatitis B 
vaccine birth dose was introduced in 2003 with financial support from the GAVI Alliance; 
the birth dose was intitially recommended to be given within 7 days after birth; in 2002, it 
was recommended to be given within 3 days after birth, and in 2006 it was recommended to 
be given within 24 h after birth, the birthdose was given at health facilities only. Since 2010, 
the subsequent hepatitis B doses are given as part of a pentavalent DPT-Hib-Hepatitis B 
vaccine schedule at ages 2, 3, and 4 months, parents were requested to bring their child to 
commune health center and outreach points (for hard to reach areas only) for vaccination.
Three-dose hepatitis B vaccine coverage has increased substantially over time from 24% in 
2000 to >90% every year starting in 2004 [13,14]. Additionally, birth dose coverage rapidly 
reached nearly 60% within 2 years after birth dose introduction in 2003. However, birth 
dose coverage declined dramatically to 29% in 2007 and 26% in 2008 following media 
reports of alleged adverse events following hepatitis B birth-dose administrtaion [13,14].
To evaluate the impact of the hepatitis B vaccination program, a survey was conducted to 
look at chronic HBV infection prevalence among children born in three time periods 
representing different hepatitis B immunization programmatic strategies and performance: 
the first period (2000–2003) represents a phased introduction of hepatitis B vaccine with low 
birth dose coverage; the second period represents high birth dose coverage and high three 
dose hepatitis B vaccine coverage (2004–2006); and the third period (2007–2008) represents 
a decrease in birth dose coverage after the media reports of alleged adverse events.
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2. Methods
2.1. Study population and design
The survey was designed to estimate HBsAg prevalence among a nationally representative 
sample of children born in three birth cohort groups: 2000–2003, 2004–2006, and 2007–
2008. Expected prevalence was assumed to be 8%, 2%, and 4% and the desired precision of 
±2%, ±1%, and ±1%, respectively. The greater sample size in the younger cohorts was 
based on a desire to have a more precise measure relating to the most recent programmatic 
activities. A design effect of 2 and non-response rate of 20% was assumed for all 3 cohorts. 
Resulting sample size was 1696 for the 2000–2003 cohort, 1807 for the 2004–2006 cohort, 
3540 for the 2007–2008 cohort and total sample size of 7044.
2.2. Sampling method and enrollment
This cross-sectional survey sampled children using a stratified three-stage cluster design. 
The district-level coverage of birth-dose given within 24 h in 2006 was used as a 
stratification variable. All 684 districts in the country were stratified into four strata of 
timely birth dose coverage: ≥50%, 25–49%; 10–24%; and <10%. Ninety-eight primary 
sampling units (districts) were allocated to the four strata based on the population size of 
each; specifically, 63, 16, 6, and 13 districts were selected in the ≥50%, 25–49%; 10–24%; 
and <10% birth dose coverage categories, respectively. Two communes were randomly 
selected from each selected district. Nine children born in years 2000–2003, nine children 
born in years 2004–2006, and 18 children born in years 2007–2008 were randomly selected 
from commune lists. District health staff and commune leaders were informed of the survey 
site selection in advance; parents received a letter requesting them to bring selected children 
and vaccination records to a designated commune health post on the survey day.
2.3. Individual-level data: questionnaire, specimen collection and testing
A questionnaire was administered to the child’s caregiver to collect basic socio-demographic 
information and vaccination history of the child. The Alere Determine™ HBsAg rapid assay 
test was used to detect HBsAg in whole blood specimens obtained from children [15]. 
Procedures were followed according to the package insert, including (1) obtaining 
approximately 50 microlitres of whole blood using a finger-prick, (2) immediately applying 
the whole blood specimen to the test strip, (3) visually reading and recording the results of 
the test strip after 15 min, and (4) confirming the test results by having a supervisor re-read 
the strip within 24 h.
2.4. Definitions
A child was considered vaccinated based on either affirmative written documentation or 
caregiver recall of vaccine doses administered. If vaccination records were reviewed and no 
entry of hepatitis B vaccination found, the child was considered unvaccinated. A child was 
considered to have a missing vaccination status if no records were available to review and a 
caregiver could not recall vaccination status.
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2.5. Data analysis
Survey teams reviewed data collection forms prior to leaving the commune to ensure all 
required data elements had been collected and were legibly recorded. The name and 
signature of the survey member reviewing the data collection forms were recorded on the 
forms to assist with monitoring the quality of data collection.
Data were double entered independently and checked for accuracy using Epidata software, 
Version 2.1b, and Epi info, version 6.04d. HBsAg seroprevalence estimates were calculated 
for subpopulations of interest using SAS 9.3. Multivariable models were fit for each of the 
three age groups separately. Prevalence ratios (PR) and 95% confidence intervals (CI) were 
calculated in SUDAAN v10. Estimates of point prevalences, PRs, and CIs accounted for 
sampling weights and stratified cluster design. Sampling weights for each child were 
calculated based on the above described sampling design.
2.6. Ethical approval
Prior to beginning the survey, the protocol was reviewed and approved by ethical review 
boards of the Western Pacific Regional Office of WHO and the National Institute of 
Hygiene and Epidemiology of Vietnam.
3. Results
3.1. Demographic characteristics of the surveyed subjects
The survey was conducted during January to February 2011 and enrolled a total of 6,962 
participants, of whom 6,949 (>99%) children met the age criteria and were included in the 
analysis. A total of 51.7% were boys; 79.5% belonged to the Kinh ethnic group. Among the 
three cohort groups, 25.0% were born from 2000 to 2003, 25.7% were born from 2004 to 
2006, and 49.3% were born from 2007 to 2008. Detailed characteristics of children enrolled 
in the survey are presented in Table 1.
3.2. HBsAg prevalence by birth cohort groups
HBsAg prevalence decreased from 3.64% (CI: 2.80–4.71) among children born in 2000–
2003 to 2.15% (CI: 1.47–3.14) among children born in 2004–2006, and to 1.64% (CI: 1.25–
2.15) among children born 2007–2008 (Table 2). Estimates of HBsAg prevalence for each 
birth year show a decline from 2000 to 2008 (Fig. 1). Children born during 2000–2003 had 
an increased risk of being HBsAg positive compared to those born during 2007–2008 (PR: 
2.22, CI: 1.55–3.18) (Table 2).
3.3. HBsAg prevalence by vaccination status
Prevalence of HBsAg by vaccination status is shown in Table 2. Infants receiving hepatitis 
B vaccine >7 days after birth had significantly higher HBsAg prevalence (3.20%) than those 
vaccinated 0–1 day after birth (1.52%) (PR: 2.09, CI: 1.27–3.46). The HBsAg prevalence 
was higher among infants vaccinated 2–7 days after birth (2.80%) compared to infants 
vaccinated 0–1 day after birth (PR: 1.86, CI: 0.68–5.06); however this difference was not 
statistically significant. For purposes of simplifying data presentation, further results are 
presented by combining the two groups and defining birth dose vaccination as vaccination 
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within 7 days of birth. Among all three birth cohorts combined, children with at least 3 
doses of hepatitis B vaccine including a birth dose had significantly lower HBsAg 
prevalence (1.75%) than those with at least 3 doses of hepatitis B vaccine but lacked a birth 
dose (2.98%) (PR: 1.71, CI: 1.00–2.91) and those who were unvaccinated (3.47%) (PR: 
1.99, CI: 1.15–3.45).
Consistent with the survey design and because of the observed differences in vaccine 
coverage and HBsAg seroprevalence in the 3 cohorts, the multivariable models were fit to 
each cohort separately (Table 3). Among the 2007–2008 cohort, the prevalence ratio 
indicates a significantly lower HBsAg prevalence among children with 3 vaccine doses 
including a birth dose compared to those with 3 doses but missing a birth dose (PR: 2.93, CI: 
1.23–6.96) and compared to those who were unvaccinated (PR: 3.01, CI: 1.04–8.70).
3.4. HBV infection prevalence by other factors
Children born at home had a significantly higher HBsAg prevalence (5.47%) compared to 
children born in health facilities (2.25%) (PR: 2.43, CI:1.68–3.51) (Table 2). In addition, 
children of ethnicity other than Kinh had a higher HBsAg prevalence (5.36%) compared to 
children with Kinh ethnicity (2.16%) (PR: 2.48, CI: 1.71–3.58). Gender and population 
density were not found to be associated with HBsAg prevalence. Ethnicity and place of birth 
were not significantly associated with seroprevalence in the multivariable models for the 
2004–2006 and 2007–2008 cohorts. Place of birth remained statistically significant in the 
2000–2003 cohort; ethnicity could not be assessed in this multivariable model due to sparse 
data (Table 3).
3.5. Coverage estimation from surveyed participants
Estimates of hepatitis B vaccine coverage (≥3 doses, with or without birth dose) were 
calculated for each cohort group and are shown in Table 4.
4. Discussion
Childhood chronic HBV infection prevalence has declined in Vietnam as a result of having a 
strong hepatitis B vaccination programme. HBsAg prevalence decreased with increasing 
coverage of hepatitis B vaccine; from 3.64% among children born in 2000–2003 to 1.64% 
among children born 2007–2008. Noting the limited comparability between the surveys, 
HBsAg prevalence found in this survey among children nationally is substantially lower 
than among 4–5 year old children in a serosurvey conducted in 1998 in Thanh Hoa Province 
(18%) [5]. If national pre-vaccine HBsAg prevalence was in the range found in Thanh Hoa 
Province, it would appear that HBsAg prevalence began to decline before birth dose 
vaccination was introduced; since the 2000–2003 cohort had only 3.6% HBsAg prevalence 
at a time when there was high 3 dose hepatitis B vaccine coverage but no or little birth dose 
vaccination was taking place. This finding serves as a reminder of the predominate mode of 
early childhood HBV transmission and the important role that a three-dose infant 
vaccination schedule can have on reducing chronic HBV infection prevalence [16].
However, high three-dose coverage in the absence of a birth dose will not likely lead 
Vietnam to reach its national and the World Health Organization’s Western Pacific Regional 
Nguyen et al. Page 5
Vaccine. Author manuscript; available in PMC 2016 January 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
hepatitis B control goal of reducing childhood chronic HBV infection prevalence to <1%. 
Even with multiple years of approximate 95% three-dose hepatitis B vaccination coverage, 
HBsAg prevalence has never dropped below 1% among vaccinated cohorts. This finding 
reinforces the need to achieve both high birth dose coverage and high three-dose hepatitis B 
vaccine coverage in Vietnam in order to achieve the goal of reducing chronic HBV infection 
prevalence to <1% [17].
The importance of birth dose vaccination is further emphasized with the finding that 
children who had at least three doses of hepatitis B vaccine including a birth dose had 
significantly lower HBsAg prevalence compared with children who had at least three doses 
of hepatitis B vaccine but were missing the birth dose. Considering the role that birth dose 
vaccination has on preventing mother-to-child transmission, it was surprising to find that the 
youngest cohort with the lowest birth dose coverage continued to have low HBsAg 
prevalence. At least two factors may have contributed to this finding including that the 
young cohort did not have the same HBV exposure opportunity during the highest risk 
period of acquiring chronic HBV infection compared with the older cohorts [18]. The 
highest risk period for acquiring chronic HBV infection has been estimated to last until 5 
years of age and the children born in 2007 and 2008 where aged 3–4 years at the time of the 
survey [17]. A second factor could be that herd immunity played a role in decreasing the risk 
of HBV infection in this youngest cohort as their older siblings had higher vaccination 
coverage and lower infection rates than older cohorts.
Conclusions herewith on hepatitis B vaccine’s impact on preventing infection largely come 
from correlating the increasing national hepatitis B immunization coverage with the 
decreasing HBsAg prevalence. It is unlikely that this decrease would be observed due to any 
other reason. However, individual-level vaccination status did not yield the same association 
in all multivariable models. This is likely a result of not having complete or accurate 
vaccination data. In addition, vaccination data quality was not likely to be homogeneous 
across all age cohorts; the older cohorts being more vulnerable to recall bias or missing 
vaccination records. It is also worth noting that birth cohort year likely served as a surrogate 
for immunization coverage and was a significant factor in predicting HBsAg prevalence in 
multivariate models.
Vietnam’s experience with the decline in birth dose vaccination coverage after highly 
publicized media reports of co-incidental neonatal deaths following vaccination serves as an 
important reminder to be prepared to inform and communicate with the media. Given over 
one quarter of neonatal deaths occur within the first 24 h of life, there will be co-incidental 
deaths occurring after vaccine administration and immunization programmes must be 
prepared for them [19]. In Vietnam, the media reports led to a decrease in uptake of birth 
dose vaccination; however, three dose vaccination coverage among older ages remained 
high. The decrease in birth dose vaccination stemmed from both refusal of vaccination from 
parents and health care workers. Vietnam’s national immunization programme used several 
approaches to raise birth dose coverage, including convening technical seminars among 
public health decision makers, re-training health-care workers, launching awareness 
campaigns on the importance birth dose vaccination. Vietnam’s birth dose coverage has 
improved reaching 55% in 2011 and 76% in 2012.
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An additional finding from the survey was that the Kinh ethnic group had lower HBsAg 
prevalence compared to other ethnic groups. This suggests a need to improve both access 
and demand for vaccine among the other ethnic groups. Many ethnic groups live in remote 
and poor conditions thereby making a vaccination visit to a health center unaffordable both 
in terms of transport costs and time. Strategies for increasing access to vaccination are 
important for improving immunization coverage in Vietnam.
Several limitations of this survey merit noting. To simplify field logistics, a rapid test with 
reported 95% sensitivity was used; therefore, true HBsAg seroprevalence may be 
underestimated. Vaccination data quality is not homogenous across age cohorts and the 
older cohorts were more vulnerable to poor record retrieval and less accurate caregiver 
recall. In addition, the youngest cohort (2007–2008) did not have the same exposure 
opportunity during the highest risk period for acquiring chronic HBV infection as the older 
cohorts and thereby may not be fully comparable.
This survey documents the impact that the hepatitis B vaccination program has had on 
reducing chronic HBV infection in children and reinforces the importance of birth dose 
vaccination. Vietnam aims to reduce chronic HBV infection prevalence in children to <1% 
and results from this survey provides valuable direction on how to proceed to strengthen an 
already highly successful programme.
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Fig. 1. 
Hepatitis B surface antigen (HBsAg) prevalence and 3-dose hepatitis B vaccine coverage by 
year of birth, 2000–2008, Vietnam. Bars indicate 95% confidence intervals.
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Table 1
Demographic characteristics of the participating survey subjects.
Demographic characteristics Category Frequency Percentage (%)
Gender Male 3,593 (51.7)
Female 3,339 (48.1)
Missing data 17 (0.2)
Population density Urban areas 1,713 (24.7)
Rural areas 5,236 (75.3)
Age group (birth year) 2000–2003 1,740 (25.0)
2004–2006 1,783 (25.7)
2007–2008 3,426 (49.3)
Ethnic group Kinh 5,527 (79.5)
Others 1,151 (16.6)
Missing data 271 (3.9)
Place born Health facility 6138 (88.3)
Home 788 (11.3)
Missing data 23 (0.3)
Total children surveyed 6,949
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Table 2
Overall and stratified hepatitis B surface antigen (HBsAg) prevalence in children born 2000–2008, Vietnam.
Factors Factor categories Surveyed number (N) HBsAg prevalence, % Prevalence ratio 95% confidence intervala
Overall 6949 2.7 NA 2.2–3.3
Gender Female 3339 2.73 1.04 0.74–1.46
Male 3593 2.63 Referent
Population density Rural areas 5236 2.84 1.25 0.76–2.06
Urban area 1713 2.27 Referent
Ethnicity Others 1151 5.36 2.48 1.71–3.58
Kinh 5527 2.16 Referent
Place of birth Home 788 5.47 2.43 1.68–3.51
Health Facility 6138 2.25 Referent
Age group (birth 
year)
2000-2003 1740 3.64 2.22 1.55–3.18
2004-2006 1783 2.15 1.31 0.86–2.01
2007–2008 3426 1.64 Referent
Birth dose vaccination Day 1946 1.52 Referent
2–7 days 418 2.80 1.86 0.68–5.06
>7 days 4558 3.20 2.09 1.27–3.46
Vaccination statusb Zero doses 1639 3.47 1.99 1.15–3.45
1–2 total doses 211 2.11 1.21 0.40–3.66
No BD and 3+ 
total doses
2764 2.98 1.71 1.001–2.91
BD and 3+ total 
doses
2305 1.75 Referent
a95% CI is around PR; except first row provides 95% CI around overall prevalence.
b
BD = birth dose and is defined as hepatitis B vaccination within 7 days of birth; Total doses includes BD.
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Table 3
Adjusted HBsAg prevalence ratiosa stratified by birth cohorts, Vietnam.
Birth cohorts Variablesb Variable categories Adjusted prevalence ratio (PR) 95% Confidence interval
2000–2003 Vaccination status Zero doses 1.34 0.54–3.28
1–2 total doses 1.20 0.13–11.07
No BD and ≥3 total doses 1.71 0.64–4.58
BD and ≥3 total doses Referent
Place of birth Home Facility 2.36 Referent 1.42–3.93
2004–2006 Vaccination status Zero doses 0.77 0.25–2.30
1–2 total doses 0.90 0.11–7.39
No BD and ≥ 3 total doses 1.10 0.52–2.36
BD and ≥ 3 total doses Referent
Place of birth Home Facility 1.93 Referent 0.57–6.57
Ethnicity Other 1.16 0.35–3.84
Kinh Referent
2007–2008 Vaccination status Zero doses 3.01 1.04–8.70
1–2 total doses 2.81 0.53–14.92
No BD and ≥3 total doses 2.93 1.23–6.96
BD and ≥3 total doses Referent
Place of birth Home 2.03 0.55–7.42
Facility Referent
Ethnicity Other 1.02 0.29–3.60
Kinh Referent
BD = birth dose, defined as HB vaccination within 7 days of birth; Total doses includes BD.
a
Prevalence ratio (PR) is the ratio of HBsAg prevalence.
b
PR adjusted for vaccination status, place of birth, and ethnicity, except for the 2000–2003 cohorts where ethnicity was omitted due to sparse data.
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Table 4
Hepatitis B vaccination coverage by birth cohort group.
Birth cohort Total children Hepatitis B vaccine 3-dose coveragea Hepatitis B vaccine birth dose coverageb
% (95% confidence interval) % (95% confidence interval)
2000–2003 1740 46.1 (39.6–52.7) 22.0 (18.1–25.9)
2004–2006 1783 78.8 (74.1–83.5) 52.7 (47.8–57.6)
2007–2008 3426 84.0 (79.6–87.7) 30.4 (26.9–33.8)
aCounting birth dose vaccination.
b
Hepatitis B vaccination within 7 days of birth.
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